Name: Understanding the Benefits of High Sensitivity Troponin for Clinicians
Start: 2020-03-31T15:00:00Z
End: 2020-03-31T15:00:15.000Z
Location: BrightTALK
Rating: 4.4

Beckman Coulter Diagnostics develops clinical diagnostic products that help advance and optimize the clinical laboratory. Beckman Coulter’s instruments, systems and tests help streamline processes to enhance efficiency, reduce costs and speed the delivery of results. 

For more than 75 years, Beckman Coulter has been a global leader devoted to providing solutions to laboratories of all sizes – offering a broad portfolio of chemistry, immunoassay, hematology, urinalysis, automation and information systems. Beckman Coulter is, and always has been, singularly devoted to moving science, innovation and the lab forward.

Watch this clinician training on-demand webinar to see Dr. Steve Ness to walk you through the clinical utility of Monocyte Distributions Width (MDW) and explain the potential benefits of using the biomarker to aid in early sepsis detection for patients in your emergency department.

Monocyte Distributions Width (MDW) Sepsis Biomarker Clinician Training

Sepsis is a prevalent, deadly, yet often elusive condition in emergency departments worldwide. Diagnosing sepsis in patients presenting with mild and non-specific initial symptoms challenges both clinical gestalt and institutional protocols, as use of biomarkers for early sepsis detection has been controversial and their utilization varies widely across countries and institutions. 

In this webinar recording hosted by Sepsis Alliance, Angela D. Craig, APN, M.S., CCNS from Cookeville Regional Medical Center and Dustin Pierce, RN, BSN, CPHQ from University of Kansas Hospital will:

• Introduce and discuss a novel hematologic parameter, MDW, recently cleared in the U.S. for sepsis detection in the emergency department
• Review current clinical evidence for MDW based on results of two large multicenter studies
• Discuss the practical implications of these results to the U.S. standards of sepsis care

Presenters:

Angela Craig, APN, M.S., CCNS 
ICU Clinical Nurse Specialist at Cookeville Regional Medical Center

Dustin Pierce, R.N., BSN, CPHQ
Quality Outcomes Coordinator at The University of Kansas Hospital

Nursing Perspective on Novel Sepsis Biomarker

Sepsis is a prevalent, deadly, yet often elusive condition in emergency departments worldwide. Despite growing recognition in significance of timely identification and guidelines-defined interventions for improvement of patients’ outcomes, diagnosing sepsis in large group of patients who present with mild and non-specific initial symptoms challenges both clinical gestalt and institutional protocols. The decades-long quest for definitive sepsis biomarkers remains largely unfulfilled and utilization of biomarkers varies widely across countries and institutions. 

In this webinar, two world-recognized emergency medicine experts in sepsis, Dr. Tiffany Osborn from Washington University, St. Louis, MO and Dr. Pierre Hausfater from Sorbonne University, Paris, France will introduce and discuss a novel hematologic parameter, Monocyte Distribution Width (MDW), recently cleared by the FDA and European Authorities for sepsis detection in the Emergency Department. MDW is available as a part of CBC with Differential test which is already routinely utilized as an early screening test for a variety of the conditions. They will discuss:

      • The current state of clinical evidence for MDW derived from the series of multicenter studies
      • The practical implications of these results to the U.S. and European standards of sepsis care          

Presenters: 

Tiffany Osborn, MD, MPH, is triple boarded in emergency medicine, U.S. critical care and European critical care.

Professor Hausfater started his career as an internal medicine specialist focused on autoimmune and inflammatory diseases.

MDW: Early Identification of Sepsis in the Emergency Department

Over-crowding at major hospitals is a major problem around the world. Dr. Seak examines the overcrowding and risk stratification in emergency department and the need for early detection of sepsis in the ED. In this webinar, Dr. Seak will discuss the importance of identifying sepsis earlier.

It may be very difficult for even the most experienced physician to detect sepsis earlier because the signs and symptoms of sepsis may be very non-specific and vague. There are many sources of infection that need to be identified and it’s often hard for emergency physicians to perform such kind of detection in very crowded, busy emergency departments. Dr. Seak looks at preliminary findings of a study examining 198 total adult patients. The primary outcome was to compare the diagnostic accuracy between MDW, WBC, and procalcitonin in predicting sepsis-2 and sepsis-3 patients.

After attending the webinar, you will be able to understand:

•Current and future detection tools for sepsis
•Learn about improved early detection of sepsis with the novel MDW biomarker
•Find out preliminary findings of the MDW study at one of the largest and busiest emergency departments in the world

MDW Biomarker Study Findings at Lin-Kou Medical Center Taiwan

Sepsis is a global problem with up to 49 million people affected by the condition worldwide.(1) The early detection of sepsis in the emergency department is a pressing problem. In this webinar, Dr. Chan-Jeoung Park, professor in the Department of Laboratory Medicine at ASAN Medical Center, University of Ulsan College of Medicine in Seoul, Korea will discuss Performance Evaluation of the Early Sepsis Indicator at ASAN Medical Center Emergency Department. Dr. Park’s clinical research examines the outcomes of 549 patients presenting to the emergency department, using sepsis-3 criteria for sepsis definition. 

After attending the webinar, you will be able to:

Learn how MDW can be an effective and sensitive biomarker for sepsis detection in patients visiting the Emergency Department (ED)
Understand the performance of MDW for sepsis detection compared to other biomarkers, Procalcitonin and C-reactive Protein  
See that the combination of MDW & WBC results can be obtained rapidly by CBC-Diff on DxH 900 and can be used as an aid in sepsis diagnosis in the ED

(1)Rudd, et al., Lancet. 2020 Jan 18; 395 (10219): 200-211.

Performance Evaluation of Early Sepsis Indicator at ASAN Medical Center ED

As the 9th leading cause of death, chronic kidney disease (CKD) causes more deaths than breast or prostate cancer in the U.S.1 Early identification and timely, comprehensive therapeutic interventions can help drastically improve patient outcomes. However, the lack of standardized processes and screening methodologies can lead to misidentification or diagnostic uncertainty. Identifying the undiagnosed renal patient within the vast number of undifferentiated patients presented to physicians is challenging and can lead to potential treatment delays with associated increases in permanent damage or mortality.

During the webinar, Dr. Steve Ness and Dawn Tobin will discuss how teamwork between lab and clinical medicine can improve patient care through accurate classification, identification and diagnosis of patients with abnormal urine casts and/or crystals. 

After this webinar, you will be able to:
•Familiarize yourself with an overview of the Renal System
•Explain the global impact & clinical importance of CKD
•Discern the different types of urinary casts & crystals and their role in assisting with patient diagnosis
•Describe the benefits of using automated digital microscopy to take the subjectivity out of urinalysis

P.A.C.E. credit is available for your participation.*

1.National Kidney Foundation. "Kidney Disease Basics."
www.kidney.org/news/newsroom/factsheets/kidneydiseasebasics. Accessed 12 Jun. 2020.

*Beckman Coulter Inc. is approved as a provider of continuing education programs in the clinical lab sciences by the ASCLS P.A.C.E.® Program. These credits are recognized by the State of California. Most programs also provide State of Florida credits (with valid license number). At this time, we cannot issue continuing education credits for those who provide healthcare (or work for an institution that provides healthcare) in Massachusetts or Vermont.

When you see Casts and Crystals ‘Urine’ Trouble

In this webinar, Dr Elliott Crouser from Ohio State University will discuss sepsis epidemiology, definitions and implications of sepsis. He will introduce a novel sepsis biomarker Monocytes Distribution Width (MDW) that is intended for an aid in early detection of sepsis in adult patients in Emergency Department. MDW available automatically as a part of the most common triage test - CBC with Differential. MDW may be of highest utility in patients with low initial clinical suspicion and high diagnostic uncertainty for sepsis. 

Additionally, you will hear Nan West, MT (ASCP) from Truman Medical Center who will share a patient case study of diagnostic challenges and importance of early identification of sepsis. Throughout the webinar the presenters will:

      1. Discuss the current state of sepsis identification in the U.S.; approaches, outcomes, and opportunities
      2. Review the novel sepsis biomarker for the emergency department MDW - available automatically as a part of CBC with Differential Test
      3. Explain role of MDW for early sepsis detection while reviewing a patient case study
      4. Describe the implementation of MDW in the clinical laboratory

Monocytes Distribution Width (MDW) New Sepsis Detection Biomarker

Sepsis is a growing healthcare crisis, causing over 11 million deaths worldwide. Early recognition and timely, comprehensive therapeutic interventions improve patient outcomes and have been codified in current clinical guidelines and government reporting requirements. However, non-specific presenting symptoms that mimic other diagnoses combined with multiple clinical definitions lead to diagnostic uncertainty. Identifying the undiagnosed septic patient within the sea of undifferentiated patients simultaneously presenting to the Emergency Department is challenging and can lead to potential treatment delays with associated increases in morbidity and mortality.

During the webinar, Dr. Osborn and Dr. Farnsworth will discuss how teamwork between the laboratory and clinical medicine can improve patient care through earlier identification and treatment of septic patients. They will discuss the challenges associated with current screening biomarkers, as well as the opportunities presented by a novel sepsis biomarker, monocyte distribution width.

After this webinar, you will be able to:
      - Explain the relationship between early sepsis treatment and improved patient mortality
      - Differentiate among Sepsis-2 and Sepsis-3 definitions and common sepsis screening criteria such as qSOFA and SIRS
      - Review published evidence supporting the effectiveness of monocyte distribution width in early sepsis detection

P.A.C.E. credit is available for your participation.*

*Beckman Coulter Inc. is approved as a provider of continuing education programs in the clinical  laboratory sciences by the ASCLS P.A.C.E.® Program. These credits are recognized by the State of California. Most programs also provide State of Florida credits (with valid license number). At this time, we cannot issue continuing education credits for those who provide healthcare (or work for an institution that provides healthcare) in Massachusetts or Vermont.

Early Sepsis Identification

You combat multidrug-resistant organisms (MDROs) and bacterial infection daily, so you know the epidemiology is evolving into a global health crisis. However, recently introduced treatments—with emerging options in the pipeline—mark a new approach in the fight against antimicrobial resistance.

Join Dr. Jean Patel, principal scientist of scientific affairs at Beckman Coulter, as she presents the status of current drugs to fight bacterial infection, updated breakpoints and an antimicrobial treatment forecast. After watching this webinar, you will be better equipped to improve patient outcomes and advance antimicrobial stewardship by understanding the benefits and limitations of:

     • Currently available MDRO treatment options
     • Emerging Gram-positive and Gram-negative bacteria solutions
     • Updated susceptibility-testing strategies

P.A.C.E. credit is available for your participation.*

Ideal For: Microbiologist, Antibiotic Stewardship Committee Member, Lab Director, Medical Director, Physician, Pathologist, Pharmacist, Infectious Disease Doctor, Infectious Disease Pharmacist, Infection Control Specialist

Presenter: Jean B. Patel, Ph.D., D(ABMM)

*Beckman Coulter Inc. is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. These credits are recognized by the State of California. Most programs also provide State of Florida credits (with valid license number). At this time, we cannot issue continuing education credits for those who provide healthcare (or work for an institution that provides healthcare) in Massachusetts or Vermont.

Multi-Drug Resistant Bacteria: A Treatment Forecast

Learn about the primary pathogens isolated in cystic fibrosis patients and consider these microorganisms’ relative antimicrobial susceptibility. How do differing intrinsic resistance values from international authorities impact antibiotic management? What interpretive category breakpoints can be used with these opportunistic, environmental pathogenic, non-fermenting, Gram-negative bacteria in cystic fibrosis patients?

In this workshop, recorded at the 29th European Congress of Clinical Microbiology & Infectious Diseases, Dr. Samantha Sottotetti explains the importance of cystic fibrosis microbiology in Gram-negative, non-fermenting bacteria isolated from the respiratory tract of cystic fibrosis patients. 

After viewing this webinar, you will be able to: 

      •Understand what bacteria colonize lungs of cystic fibrosis patients, and how MIC testing is performed
      •Identify characteristics of colonization and phenotypes of P. aeruginosa, the major Gram-negative organism
      •Describe other opportunistic pathogens—including A. xylosidans, S. maltophilia and B. cepacia—and antibiotic resistance for each organism
 
P.A.C.E. credit is available for your participation.* 

Ideal For: Microbiologist, Laboratory Director, Physician, Pathologist 

Presenter: Professor Dr. Samantha Sottotetti, Cystic Fibrosis Microbiology Laboratory

*Beckman Coulter Inc. is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. These credits are recognized by the State of California. Most programs also provide State of Florida credits (with valid license number). At this time, we cannot issue continuing education credits for those who provide healthcare (or work for an institution that provides healthcare) in Massachusetts or Vermont.

Microbiology of Gram-negative Bacteria in Cystic Fibrosis

Using Hematology Assays to Assess Sepsis Risk

Understand the challenges you will confront when interpreting antibiotic susceptibility test results based on minimum inhibitory concentration (MIC) accuracy. Ignoring uncertainty introduced through multiple factors—interlaboratory variability, biological differences, incubation temperature fluctuations, time ranges, proximity to breakpoints and others—influences the results of antimicrobial susceptibility test results.

In the webinar, Accuracy of MICs, recorded at the 29th European Congress of Clinical Microbiology & Infectious Diseases, Professor Dr. Sören Gatermann will review how correct classification of antibiotic resistance demands a persistent, multifaceted approach to analysis.

After viewing this webinar, you will be able to:

   - Understand the sources of uncertainty in phenotypic antimicrobial susceptibility testing—variability between laboratories, bacterial variation, incubation temperatures, MIC breakpoint interpretation and others
   - Learn about the new “Area of Technical Uncertainty” and other factors involved in setting EUCAST breakpoints
   - Know the reasons behind some EUCAST breakpoints having no susceptible MIC interpretation

P.A.C.E. credit is available for your participation.*

Ideal for: Microbiologist, Pharmacist, Medical Director, Laboratory Director, Pathologist, Physician

Presenter:  Sören Gatermann, Abteilung für Medizinische Microbiologie der Ruhr-Universität Bochum

*Beckman Coulter Inc. is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. These credits are recognized by the State of California. Most programs also provide State of Florida credits (with valid license number). At this time, we cannot issue continuing education credits for those who provide healthcare (or work for an institution that provides healthcare) in Massachusetts or Vermont.

Accuracy of MICs

Explore how systematic collection, analysis, interpretation and timely dissemination of minimum inhibitory concentration (MIC) data impacts the planning, implementation and evaluation of public health practice. Understand what impact high-level or low-level resistance mechanisms have on the interpretation of isolates distribution, which may help clinicians go beyond relying solely upon the breakpoints available today. 

In this webinar, recorded at the 29th European Congress of Clinical Microbiology & Infectious Diseases, hear Professor Rafael Canton review why antimicrobial resistance, beyond the human side of medicine, is yet another public health approach clinicians need to address.

After viewing this webinar, you will be able to:

   - Learn the importance of surveillance of antimicrobial resistance, and the international programs for antimicrobial resistance surveillance
   - Understand the importance of MIC interpretation in public health surveillance, with examples for fluoroquinolones and cephalosporins
   - Know how MICs can assist the user in simplification of complex resistance mechanisms, and the relevance of MICs when using molecular methods for surveillance

P.A.C.E. credit is available for your participation.*

Ideal for: Antimicrobial Stewardship Committee Member, Laboratory Director, Microbiologist

Presenter:  Rafael Canton, Hospital Universitario Ramón y Cajal-IRYCIS 

*Beckman Coulter Inc. is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. These credits are recognized by the State of California. Most programs also provide State of Florida credits (with valid license number). At this time, we cannot issue continuing education credits for those who provide healthcare (or work for an institution that provides healthcare) in Massachusetts or Vermont.

MIC Surveillance, Resistance Mechanisms and Public Health

In this webinar, Dr. Ranjana Hawaldar will discuss a solution to help laboratories screen out samples that will not grow pathogenic bacteria prior to urine culture analysis. With this feature, laboratories can experience short TATs for negative results and support antimicrobial stewardship by helping to reduce the need for non-specific antibiotic treatment. 

After watching the presentation, you will be able to:
    - Discuss how UTIs impact healthcare settings and laboratory workloads
    - Review current alternatives for UTI testing
    - Assess the relevant factors associated with urine culture candidate screening
    - Propose strategies to introduce a urine culture candidate screening process in the laboratory to avoid unnecessary urine cultures

P.A.C.E. credit is available for your participation.*

Presenter: Ranjana Hawaldar, M.B.B.S., M.D.

*Beckman Coulter Inc. is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. These credits are recognized by the State of California. Most programs also provide State of Florida credits (with valid license number). At this time, we cannot issue continuing education credits for those who provide healthcare (or work for an institution that provides healthcare) in Massachusetts or Vermont.

Maximizing Productivity in Urinary Tract Infection Testing

For decades, cardiac troponin has been the preferred biomarker for helping to detect myocardial injury  in acute care settings. The evolution of technology has led to the development of high sensitivity troponin  assays that have greater precision at clinical decision points and enable lower limits of detection. This enhances clinicians’ ability to rule in or rule out acute myocardial infarction for timely intervention. Because of this, in 2018, “The Fourth Universal Definition of Myocardial Infarction” updated its guidelines to recommend the use of high sensitivity cardiac troponin assays that meet the precision criteria of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).1 

Understanding the clinical utility and differences in high sensitivity cardiac troponin assays, compared to previous generation products, is vital to their implementation in the healthcare system. Cardiac troponin values , whole number reporting, the presence of acute ischaemia  in patients presenting with chest pain, and sex-specific cutoffs all play a role in AMI diagnosis  using high sensitivity troponin testing.

This webinar explores these and other topics to provide an overview of the benefits of high sensitivity cardiac troponin assays. Better understanding of the capabilities and value of this technology can further its adopting and success in clinical practice.

Understanding the Benefits of High Sensitivity Troponin for Clinicians

hstni

high sensitivity troponin

cardiac injury

The medical research community on BrightTALK brings together medical and research professionals. Find relevant webinars on medical research, laboratory science, continuing medical education and more presented by recognized medical researchers. Join the conversation by participating in live webinars and round table discussions on the latest in medical devices, medical research practices and trends in the healthcare industry.

Medical Research

Thousands of healthcare IT professionals compose the health IT community on BrightTALK. Learn alongside them with relevant webinars on healthcare IT compliance, big data in healthcare and IT solutions for healthcare organizations. Join the conversation by asking questions and engaging with other participants during live webinars and organized discussions.

Health IT

Get powerful life science insights from influential experts. Connect with thought leaders and colleagues to get the most up-to-date knowledge on strategies and initiatives to accelerate the transformation of U.S. and global health care from a volume- to value-based marketplace.

Understanding the Benefits of High Sensitivity Troponin for Clinicians

Presented by

About this talk

More from this channel